# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 81-90 of 614 results.
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
Status: Recruiting
Last Changed: Sep 26, 2019
First Received: Jan 22, 2019
Disease(s): Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Intervention(s): 18F-DCFPyL
Locations: Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients
Status: Not yet recruiting
Last Changed: Jan 10, 2020
First Received: Jan 10, 2020
Disease(s): Ovarian Neoplasms
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
Status: Recruiting
Last Changed: Aug 20, 2019
First Received: Apr 02, 2019
Disease(s): Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Intervention(s): Neoadjuvant chemotherapy+Durvalumab+Tremelimumab
Locations: National Cancer Center, Korea, Gyeonggi-do, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
Status: Not yet recruiting
Last Changed: Jan 11, 2018
First Received: Sep 07, 2017
Disease(s): Ovarian Cancer Stage IV
Intervention(s): Pembrolizumab Injectable Product - Chemotherapy - Bev, Chemotherapy - Bev
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Status: Recruiting
Last Changed: Feb 08, 2019
First Received: Apr 18, 2017
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Cediranib, Paclitaxel
Locations: Belfast City Hospital, Belfast, County Antrim, United Kingdom
Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
City Hospital Nottingham, Nottingham, Nottinghamshire, United Kingdom
Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
Royal United Hospital, Bath, United Kingdom
... and 10 other locations.
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Status: Recruiting
Last Changed: Nov 19, 2019
First Received: May 14, 2019
Disease(s): Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Intervention(s): ChemoID Assay, Standard Chemotherapy
Locations: Arizona Oncology, Phoenix, Arizona, United States
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
West Penn Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
... and 3 other locations.
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
Status: Recruiting
Last Changed: Dec 03, 2019
First Received: Jan 12, 2018
Disease(s): Recurrent Platinum Resistant Ovarian Cancer
Intervention(s): VB-111 + Paclitaxel, Placebo + Paclitaxel
Locations: Western Regional Medical Center, Goodyear, Arizona, United States
Arizona Oncology Associates, PC - HAL - USO, Phoenix, Arizona, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
University of Southern California, Los Angeles, California, United States
UCLA-JCCC-Women's Health Clinical Research Unit, Los Angeles, California, United States
... and 51 other locations.
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
Status: Recruiting
Last Changed: Aug 20, 2019
First Received: Jan 09, 2018
Disease(s): Ovarian Cancer, Ovarian Neoplasms
Intervention(s): Atezolizumab, Carboplatin, Paclitaxel, Bevacizumab
Locations: Duke Cancer Institute, Durham, North Carolina, United States
University of Virginia, Charlottesville, Virginia, United States
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Feb 08, 2019
First Received: Jan 19, 2017
Disease(s): Ovarian Cancer, Epithelial
Intervention(s): CC0 - Carboplatin (IV) - Paclitaxel (IV), CC0 - Cisplatin (IP) - Epirubicin (IV), CC>0 - Carboplatin (IV)- Paclitaxel (IV), CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
Locations: Centre Georges François Leclerc, Dijon, France
Institut Hospitalier Franco-Britannique, Levallois-Perret, France
Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France
Hôpital Saint Antoine, Paris, France
Hôpital Poissy Saint Germain, Poissy, France
... and 3 other locations.
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Oct 08, 2019
First Received: Jul 06, 2018
Disease(s): Ovarian Cancer Stage IV, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IIIb
Intervention(s): Retarded IDS (Interval Debulking Surgery), Standard IDS (Interval Debulking Surgery)
Locations: ICO Paul Papin, Angers, France
ICA - Polyclinique Urbain V, Avignon, France
Institut Bergonié, Bordeau, France
Hôpital Morvan - Centre Hospitalier Universitaire, Brest, France
Centre François Baclesse, Caen, France
... and 21 other locations.